Full-Time

Director – IS Commercial and Medical Field Solutions

Posted on 10/16/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS cancers

Compensation Overview

$210k - $253k/yr

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Salesforce
Requirements
  • Mastery of principles and technologies of Customer Relationship Management platforms in life sciences (e.g., Veeva, Salesforce.com, IQVIA OCE).
  • Strong leadership skills with direct people management experience in building and managing cross-functional teams.
  • Experience in building and supporting CRM systems in both sales and service functions.
  • Deep experience with sales and medical engagement processes; Health Care Provider (HCP) and Key Opinion Leader (KOL) engagement, lead and opportunity management, territory alignments, performance management, insight collection and analysis.
  • Has led and contributed to multiple platform integrations, both real time and batch, between a CRM and data warehouse, content management (Veeva PromoMats/MedComms), Marketing Automation, and 3rd party applications.
  • Strong understanding of internal and external sales and marketing data sources leveraged in a Commercial setting (ERP, Website, Hub, Specialty Pharmacy, Diagnostics, secondary data, reference data, etc.)
  • Experience delivering field suggestions/next best action capabilities.
  • Entrepreneurial, driven and accountable self-starter, with ability to identify and communicate priorities, and work independently in a fast-paced, rapidly growing organization.
  • High levels of organization, attention to detail, and accuracy. Driven to meet and exceed high expectations of quality.
  • Build rapport and credibility as a strategic partner by demonstrating subject matter expertise in both business subject areas and application functionality.
  • Excellent communication skills, possessing the ability to prepare and present information and solutions in a visually appealing and easy to understand manner to all levels of management and staff.
  • Ability to manage a portfolio of projects, activities, and tasks simultaneously and autonomously.
  • Understanding of master data management (MDM) and data warehousing principles and technologies.
  • Bachelor’s degree or equivalent and a minimum of 12 years in the delivery of technology services and support, including Commercial experience.
  • Five years of experience implementing, customizing, and configuring a CRM.
  • Experience in pharma, life sciences, or a related industry.
Responsibilities
  • Lead the design, implementation, and maintenance of Commercial and Medical Affairs field team platforms and tools.
  • Build and manage a high performing team of CRM administrators, developers, and business analysts leveraging a combination of in-house and outsourced resources.
  • Partner with leadership and end users (Sales, Medical Affairs, Marketing, Market Access, Analytics and Sales Operations) teams to define user business and system needs.
  • Evaluate business challenges and effectively design, estimate, propose, recommend, and deliver solutions in the CRM ecosystem by using their in-depth understanding of customers, business model, products, and KPIs.
  • Enable seamless and easy to use field enablement, allowing for interactive visual aids and closed loop marketing in a mobile experience.
  • Partner with marketing to deliver campaigns and Omnichannel experiences.
  • Ensure the reliability, accuracy, and compliance of data across the CRM.
  • Responsible for the overall quality of field information systems. Troubleshoot and resolve system and data issues.
  • Develop reports/dashboards for field operations.
  • Support sales and operations in the execution of business planning from the national, regional, and territory levels.
  • Provide end-user training and support for field, marketing, and operations colleagues to leverage the CRM system and data.
  • Employ enterprise thinking in collaborating with vendors and consultants to establish and optimize information systems.
  • Foster a culture of continuous improvement and innovation within the Information Systems team.
  • Stay informed about emerging technologies, industry trends, and best practices.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

10%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.

INACTIVE